South Korean Pharma Firms Secured Top APAC Deal Rankings
Three South Korean companies placed in the top 10 for pharmaceutical transactions by securing high-value licensing and acquisition agreements.
Updated on Oct. 5, 2026 in Healthcare
Live Poll
Should the public trust large-scale pharmaceutical mergers and technology deals to lower long-term drug costs?
Samsung Biologics, SK Biopharmaceuticals, and Hanmi Pharmaceutical earned top spots in the 2026 Biopharma APAC deal rankings for their significant roles in regional pharmaceutical transactions. These rankings evaluated market influence and capital structure for activity occurring between January and September 2026.
Why it matters
The rankings highlight how regional players are capturing global market share through high-stakes technology transfers and acquisitions. For operators, the shift underscores the importance of balancing conditional milestone payments against guaranteed capital in cross-border biotech partnerships.
Seven technology transfer and licensing deals reached $54.4 billion in total value against $4.5 billion in confirmed payments. Additionally, three major M&A transactions in the top 10 accounted for approximately $16 billion in fully confirmed capital.
The players
Samsung Biologics
A contract development and manufacturing organization that provides end-to-end services for pharmaceutical and biotechnology companies.
Hanmi Pharmaceutical
A South Korean developer of innovative drug candidates and global technology transfer partnerships.
SK Biopharmaceuticals
A biopharmaceutical company focused on the discovery and development of treatments for central nervous system disorders.
AstraZeneca
A global science-led biopharmaceutical company focused on the discovery and commercialization of prescription medicines.
Novartis
A Swiss multinational pharmaceutical corporation engaged in research, development, and manufacturing of healthcare products.
The details
Rankings were assigned based on strategic influence, precedent-setting impact, and the quality of capital involved. South Korean firms leveraged these agreements to anchor their presence in global markets, such as Hanmi Pharmaceutical’s $2.3 billion transfer with Genentech. The evaluation criteria prioritized transactions that demonstrated structural stability through a higher proportion of confirmed payments relative to contingent milestones.
Timeline
January 2026 - September 2026: Period evaluated for Biopharma APAC deal rankings.
July 2026: Samsung Biologics reached an agreement to acquire PolyPeptide Group.
September 2026: Alteogen signed a contract with Novartis.
Market Landscape
The 2026 Biopharma APAC deal influence rankings illustrate a growing preference for technology transfer agreements over pure-play venture capital in the region. This development marks a departure from historic venture investment dominance by highlighting the rise of large-scale technology transfers.
Operators should monitor the shift toward high-value technology transfer agreements when assessing potential partnership risks or rewards. Review your company's contract structures to ensure you understand the exact ratio of upfront versus milestone-based payments in cross-border deals.
The takeaway
The rise of South Korean firms in global deal rankings underscores the maturity of the regional pharmaceutical sector in executing complex, high-capital transactions. Track the proportion of confirmed versus conditional capital in your next licensing or M&A negotiation to ensure financial stability.
Further reading
For broader context on current industry shifts, see Healthcare.
Live Poll
Should the public trust large-scale pharmaceutical mergers and technology deals to lower long-term drug costs?
